The UC Pancreatic Cancer Consortium (UCPCC) creates a highly collaborative environment to accelerate the progress and impact of work in pancreatic cancer by scientists and clinicians across UC’s five NCI-designated Comprehensive Cancer Centers.
Upcoming events
UC Pancreatic Cancer Consortium Symposium
Post-Pandemic Progress in Pancreatic Cancer Research
December 15, 2023
Location: UC Irvine
Registration and full details available here.
Funding Opportunities
The UC Pancreatic Cancer Consortium supports pilot projects to encourage collaboration between UC campuses. RFPs will be posted here. For additional information or guidance, contact Kurt Giles.
Pilot awards
2023
Germline Testing in Pancreatic Neuroendocrine Tumors: Emily Bergsland (UCSF), Joel (Randy) Hecht (UCLA), and Paul Fanta (UC San Diego)
2022
Development and Validation of an Artificial Intelligence Platform to Predict Negative-Margin (R0) Resectability of Pancreatic Ductal Adenocarcinoma Based on Preoperative CT Scans: Adnan Alseidi (UCSF) and Timothy Donahue (UCLA)
2021
Defining the metabolic vulnerabilities of chemoresistant pancreatic cancer: Christopher Halbrook (UCI) and Herve Tiriac (UC San Diego)
About us
Our vision is to improve the lives of people diagnosed with pancreatic cancer by translating innovative research into improved clinical care.
Leadership
UC Davis Comprehensive Cancer Center
Edward Kim, M.D.
Gerardo Mackenzie, Ph.D.
UC Irvine Chao Family Comprehensive Cancer Center
Christopher Halbrook Ph.D.
Jennifer Valerin M.D., Ph.D.
UCLA Jonsson Comprehensive Cancer Center
Timothy Donahue, M.D.
Zev Wainberg M.D.
UC San Diego Moores Cancer Center
Andrew Lowy, M.D.
Gregory Botta, M.D., Ph.D.
UCSF Helen Diller Family Comprehensive Cancer Center
Margaret Tempero, M.D.
Rushika Perera, Ph.D.
Working groups
- Biobanking
- Early Biology
- Early Detection
- Imaging
- Inherited Susceptibility
- PDAC Clinical Trials
- Technology Assessment
- PNET